E-therapeutics Plc
ETXPFOTCHealthcare
$0.13
+$0.00(+0.00%)
Market Cap$75963547
P/E Ratio—
52W High$0.13
52W Low$0.13
E-therapeutics Plc (ETXPF) Earnings: Dates, EPS & Revenue History
Quarterly EPS vs. estimates, revenue surprises, next earnings date, and analyst consensus.
ETXPF · earnings · updated Jun 9, 2026
Latest Earnings
Q3 FY2024Report Date: Jul 31, 2024EPS Actual
-$0.01
Revenue
—
Fiscal Period
Q3 FY2024
FY ends December
Report Date
Jul 31, 2024
After Market Close
ETXPF reports quarterly as a OTC-listed Biotechnology company. Fiscal year ends in December. Data: FMP · Updated hourly.
Next Earnings Date
Days Away
84
days
Expected Date
Sep 1, 2026
Fiscal Period
Q3 FY2026
Release Time
◌ Time TBD (Unconfirmed)EPS Est.
$1.00
Rev. $1.80B
Days Away84
Expected DateSep 1, 2026
Fiscal PeriodQ3 FY2026
Release TimeTime TBD (Unconfirmed)
EPS Est.$1.00
Rev. Est.$1.80B
EPS & Revenue vs. Estimates
Actual (Beat)
Actual (Miss)
Estimated
Earnings History
| Period | Report Date | EPS Est. | EPS Actual | EPS Surpr. | Revenue | Rev. Est. | Rev. Surpr. |
|---|---|---|---|---|---|---|---|
| — Q3 FY2024 | Jul 31, 2024 | — | -$0.01 | — | — | — | — |
| — Q2 FY2024 | Apr 29, 2024 | — | -$0.01 | — | $0.00B | — | — |
| — Q3 FY2023 | Jul 31, 2023 | — | -$0.01 | — | $0.00B | — | — |
| — Q1 FY2023 | Jan 31, 2023 | — | -$0.01 | — | $0.00B | — | — |
| — Q3 FY2022 | Jul 31, 2022 | — | -$0.01 | — | $0.00B | — | — |
| — Q1 FY2022 | Jan 31, 2022 | — | -$0.01 | — | — | — | — |
| — Q3 FY2021 | Jul 31, 2021 | — | -$0.01 | — | $0.00B | — | — |
| — Q1 FY2021 | Jan 31, 2021 | — | -$0.00 | — | $0.00B | — | — |
Q3 FY2024
Jul 31, 2024
EPS Actual
-$0.01
EPS Est.
—
EPS Surpr.
—
Revenue
—
Q2 FY2024
Apr 29, 2024
EPS Actual
-$0.01
EPS Est.
—
EPS Surpr.
—
Revenue
$0.00B
Q3 FY2023
Jul 31, 2023
EPS Actual
-$0.01
EPS Est.
—
EPS Surpr.
—
Revenue
$0.00B
Q1 FY2023
Jan 31, 2023
EPS Actual
-$0.01
EPS Est.
—
EPS Surpr.
—
Revenue
$0.00B
Q3 FY2022
Jul 31, 2022
EPS Actual
-$0.01
EPS Est.
—
EPS Surpr.
—
Revenue
$0.00B
Q1 FY2022
Jan 31, 2022
EPS Actual
-$0.01
EPS Est.
—
EPS Surpr.
—
Revenue
—
Q3 FY2021
Jul 31, 2021
EPS Actual
-$0.01
EPS Est.
—
EPS Surpr.
—
Revenue
$0.00B
Q1 FY2021
Jan 31, 2021
EPS Actual
-$0.00
EPS Est.
—
EPS Surpr.
—
Revenue
$0.00B
Analyst Estimates
EPS Estimates
| Period | Low | Consensus | High | # Analysts |
|---|
Revenue Estimates
| Period | Low | Consensus | High | # Analysts |
|---|
Earnings Price Reaction
Closing price one trading day before vs. one trading day after each earnings release.
| Period | Report Date | EPS Beat/Miss | Price Before | Price After | 1D Reaction |
|---|---|---|---|---|---|
| — Q3 FY2024 | Jul 31, 2024 | — | $0.13 | — | — |
| — Q2 FY2024 | Apr 29, 2024 | — | $0.13 | — | — |
| — Q3 FY2023 | Jul 31, 2023 | — | $0.29 | $0.29 | +0.00% |
| — Q1 FY2023 | Jan 31, 2023 | — | $0.24 | $0.24 | +0.00% |
| — Q3 FY2022 | Jul 31, 2022 | — | $0.26 | $0.26 | +0.00% |
| — Q1 FY2022 | Jan 31, 2022 | — | $0.45 | $0.45 | +0.00% |
| — Q3 FY2021 | Jul 31, 2021 | — | $0.23 | $0.23 | +0.00% |
| — Q1 FY2021 | Jan 31, 2021 | — | $0.23 | $0.23 | +0.00% |
Q3 FY2024—
Report Date
Jul 31, 2024
EPS Beat/Miss
—
Price Before
$0.13
Price After
—
Q2 FY2024—
Report Date
Apr 29, 2024
EPS Beat/Miss
—
Price Before
$0.13
Price After
—
Q3 FY2023+0.00%
Report Date
Jul 31, 2023
EPS Beat/Miss
—
Price Before
$0.29
Price After
$0.29
Q1 FY2023+0.00%
Report Date
Jan 31, 2023
EPS Beat/Miss
—
Price Before
$0.24
Price After
$0.24
Q3 FY2022+0.00%
Report Date
Jul 31, 2022
EPS Beat/Miss
—
Price Before
$0.26
Price After
$0.26
Q1 FY2022+0.00%
Report Date
Jan 31, 2022
EPS Beat/Miss
—
Price Before
$0.45
Price After
$0.45
Q3 FY2021+0.00%
Report Date
Jul 31, 2021
EPS Beat/Miss
—
Price Before
$0.23
Price After
$0.23
Q1 FY2021+0.00%
Report Date
Jan 31, 2021
EPS Beat/Miss
—
Price Before
$0.23
Price After
$0.23
Beat Rate0 / 8 quarters
Largest Move+0.00% (Q3 FY2023)
Data: FMP /historical-price-eod/full · field: close
About Earnings & Data Methodology
Data source: Financial Modeling Prep (FMP) | Updated: Hourly | Surprise%: (Actual − Estimate) / |Estimate| × 100 | Fiscal year: ETXPF ends December
E-therapeutics Plc (ETXPF) most recently reported earnings on July 31, 2024 for Q3 FY2024, posting EPS of $-0.01 (in line with the analyst consensus of —). The next ETXPF earnings date is expected around September 1, 2026.
Each quarter, investors track ETXPF earnings for signals on forward guidance and business momentum. For longer-term revenue trends, see the Revenue tab. ETXPF revenue tab →
Earnings Glossary
EPS (Earnings Per Share)
Net income ÷ diluted shares outstanding. The primary metric analysts use to gauge quarterly profitability.
Earnings Surprise %
(Actual − Estimate) / |Estimate| × 100. Positive = Beat. Negative = Miss.
Beat / Miss / In-Line
Beat = Actual ≥ Estimate. Miss = Actual < Estimate. In-Line = within ±1%.
BMO / AMC
Before Market Open / After Market Close. Two windows when companies typically release results.
Fiscal Quarter
ETXPF's fiscal year ends in December. Fiscal quarters may not align with calendar quarters.
Analyst Consensus
Average EPS/Revenue forecast across all covering analysts. More analysts = more reliable estimate.
Figures tie to FMP earnings calendar, estimates, and SEC 10-Q/10-K filings where noted.
Frequently asked questions
ETXPF earnings · 4 questionsE-therapeutics Plc's next earnings report is expected around September 1, 2026. ETXPF typically reports quarterly — approximately every three months. The exact date is confirmed by the company 2–4 weeks before the release. Time is currently TBD; ETXPF historically reports after market close (AMC).
ETXPF earnings datewhen is ETXPF earningsETXPF next earnings datewhen does ETXPF report earningsETXPF earnings calendar
▸ Source: FMP · E-therapeutics Plc SEC filings · US GAAP · E-therapeutics Plc SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 9, 2026